Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.The Motley Fool • 09/06/26
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to KnowZacks Investment Research • 09/03/26
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're WrongThe Motley Fool • 09/03/26
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.The Motley Fool • 08/30/26
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?Zacks Investment Research • 08/28/26
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?The Motley Fool • 08/27/26
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?Zacks Investment Research • 08/17/26
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)Seeking Alpha • 08/07/26
Viking Therapeutics Declined in July, and why its Long-Term Prospects are UndiminishedThe Motley Fool • 08/06/26
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover TargetThe Motley Fool • 07/30/26
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • 07/29/26
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?Zacks Investment Research • 07/28/26
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026PRNewsWire • 07/22/26
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1The Motley Fool • 07/18/26
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes.The Motley Fool • 07/18/26
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteZacks Investment Research • 07/17/26